Highlights beim myelodysplastischen Syndrom

Sie sehen gerade einen Platzhalterinhalt von Vimeo. Um auf den eigentlichen Inhalt zuzugreifen, klicken Sie auf die Schaltfläche unten. Bitte beachten Sie, dass dabei Daten an Drittanbieter weitergegeben werden.

Mehr Informationen

Hochrisiko-MDS

Immuntherapie

  • Anti-CD47-Antikörper Magrolimab

The First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine Is Well-Tolerated And Effective In MDS Patients: Phase 1b Results. Sallman David et al., EHA25 virtual, Abstr. #S187

  • Anti-Tim-3-Antikörper MBG453

Anti-TIM-3 Antibody MBG453 In Combination With Hypomethylating Agents (HMAs) In Patients (Pts) With High-Risk Myelodysplastic Syndrome (HR-MDS) And Acute Myeloid Leukemia (AML): A Phase 1 Study. Uma Borate et al., EHA25 virtual, #Abstr S185

Zielgerichtete Therapie

  • APR-246Target ist mutiertes p53

APR-246 Combined With Azacitidine In Tp53 Mutated Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukemia. A Phase 2 Study By The Groupe Francophone Des Myélodysplasies (GFM). Thomas Cluzeau et al., EHA25 virtual, Abstr. # S181

  • bcl2-Hemmer Venetoclax

A Phase 1b Study Evaluating The Safety And Efficacy Of Venetoclax In Combination With Azacitidine For The Treatment Of Relapsed/Refractory Myelodysplastic Syndrome. Amer M. Zeidan et al., EHA25 virtual, Abstr. #S188

  • Proteasomeninhibitor Pevonedistat

Phase 2 Study Of Pevonedistat + Azacitidine Versus Azacitidine In Patients With Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia Or Low-Blast Acute Myelogenous Leukemia. Lionel Ades et al., EHA25 virtual, Abstr. #S182

Niedrigrisiko-MDS

  • Luspatercept bei hoher Transfusionslast – Auswertung der MEDALIST-Studie (Zeidan et al.)

Clinical Benefit Of Luspatercept In Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) And High Transfusion Burden (HTB) In The Phase 3 MEDALIST Study. Amer M. Zeidan et al., EHA25 virtual, Abstr. # EP798

  • Dosisabhängiges Ansprechen auf Luspatercept – Auswertung der MEDALIST-Studie (Platzbecker et al.)

Assessment Of Dose-Dependent Response To Luspatercept In Patients (Pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) With Ring Sideroblasts In The Phase 3 MEDALIST Trial. Uwe Platzbecker et al., EHA25 virtual, Abstr. #EP812

  • Telomerase-Inhibitor Imetelstat 

https://library.ehaweb.org/eha/2020/eha25th/295003/uwe.platzbecker.treatment.with.imetelstat.provides.durable.transfusion.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dtelomerase+inhibitor